William Lewis - 02 Jan 2025 Form 4 Insider Report for INSMED Inc (INSM)

Role
Chair and CEO, Director
Signature
/s/ William Lewis, by Michael A. Smith as Attorney-in-fact
Issuer symbol
INSM
Transactions as of
02 Jan 2025
Net transactions value
-$1,285,788
Form type
4
Filing time
03 Jan 2025, 18:52:40 UTC
Previous filing
20 Dec 2024
Next filing
08 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INSM Common Stock Options Exercise $426,750 +18,750 +4.9% $22.76 403,710 02 Jan 2025 Direct F1
transaction INSM Common Stock Sale $1,309,500 -18,750 -4.6% $69.84 384,960 02 Jan 2025 Direct F1, F2
transaction INSM Common Stock Options Exercise $74,106 +6,830 +2.9% $10.85 240,754 02 Jan 2025 By the Katie Procter Dynasty Trust F1
transaction INSM Common Stock Sale $477,144 -6,830 -2.8% $69.86 233,924 02 Jan 2025 By the Katie Procter Dynasty Trust F1, F3
holding INSM Common Stock 50,500 02 Jan 2025 By the William Lewis Family Legacy Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INSM Stock Option (right to buy) Options Exercise $0 -18,750 -17% $0.000000 93,750 02 Jan 2025 Common Stock 18,750 $22.76 Direct F1, F4
transaction INSM Stock Option (right to buy) Options Exercise $0 -6,830 -2.9% $0.000000 225,460 02 Jan 2025 Common Stock 6,830 $10.85 By the Katie Procter Dynasty Trust F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2 This is the weighted average sales price representing 18,750 shares sold at prices ranging from $69.45 to $70.37 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
F3 This is the weighted average sales price representing 6,830 shares sold at prices ranging from $69.48 to $70.37 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
F4 The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable.